{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:42:58Z","timestamp":1781664178794,"version":"3.54.5"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00467-023-06102-w","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T17:02:02Z","timestamp":1690304522000},"page":"315-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6281-5713","authenticated-orcid":false,"given":"Dermot Michael","family":"Wildes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caoimhe Suzanne","family":"Costigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clodagh","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ilis","family":"Twomey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atif","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen Mary","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"6102_CR1","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035\u20131050","journal-title":"J Am Soc Nephrol"},{"key":"6102_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3201\/eid1104.040833","volume":"11","author":"RM Lynn","year":"2005","unstructured":"Lynn RM, O\u2019Brien SJ, Taylor CM et al (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590\u2013596","journal-title":"Emerg Infect Dis"},{"key":"6102_CR3","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00431-021-04200-1","volume":"181","author":"C Costigan","year":"2022","unstructured":"Costigan C, Raftery T, Carroll AG et al (2022) Neurological involvement in children with hemolytic uremic syndrome. Eur J Pediatr 181:501\u2013512","journal-title":"Eur J Pediatr"},{"key":"6102_CR4","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1007\/s00467-018-4105-1","volume":"34","author":"M Khalid","year":"2019","unstructured":"Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34:2495\u20132507","journal-title":"Pediatr Nephrol"},{"key":"6102_CR5","doi-asserted-by":"publisher","first-page":"e2020013631","DOI":"10.1542\/peds.2020-013631","volume":"147","author":"CC Brown","year":"2021","unstructured":"Brown CC, Garcia X, Bhakta RT, Sanders E, Prodhan P (2021) Severe acute neurologic involvement in children with hemolytic-uremic syndrome. Pediatrics 147:e2020013631","journal-title":"Pediatrics"},{"key":"6102_CR6","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1007\/s00467-018-4025-0","volume":"34","author":"PR Walsh","year":"2019","unstructured":"Walsh PR, Johnson S (2019) Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome. Pediatr Nephrol 34:1485\u20131492","journal-title":"Pediatr Nephrol"},{"key":"6102_CR7","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF et al (2007) Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25:1256\u20131264","journal-title":"Nat Biotechnol"},{"key":"6102_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00431-017-3077-7","volume":"177","author":"W Keenswijk","year":"2018","unstructured":"Keenswijk W, Raes A, Vande Walle J (2018) Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence. Eur J Pediatr 177:311\u2013318","journal-title":"Eur J Pediatr"},{"key":"6102_CR9","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMc1100859","volume":"364","author":"AL Lapeyraque","year":"2011","unstructured":"Lapeyraque AL, Malina M, Fremeaux-Bacchi V et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561\u20132563","journal-title":"N Engl J Med"},{"key":"6102_CR10","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/cid\/cis531","volume":"55","author":"S Loos","year":"2012","unstructured":"Loos S, Ahlenstiel T, Kranz B et al (2012) An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children. Clin Infect Dis 55:753\u2013759","journal-title":"Clin Infect Dis"},{"key":"6102_CR11","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1007\/s00467-014-2803-x","volume":"29","author":"A Bauer","year":"2014","unstructured":"Bauer A, Loos S, Wehrmann C et al (2014) Neurological involvement in children with E. coli O104:H4-induced hemolytic uremic syndrome. Pediatr Nephrol 29:1607\u20131615","journal-title":"Pediatr Nephrol"},{"key":"6102_CR12","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/dmcn.12161","volume":"55","author":"C Gitiaux","year":"2013","unstructured":"Gitiaux C, Krug P, Grevent D et al (2013) Brain magnetic resonance imaging pattern and outcome in children with haemolytic-uraemic syndrome and neurological impairment treated with eculizumab. Dev Med Child Neurol 55:758\u2013765","journal-title":"Dev Med Child Neurol"},{"key":"6102_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.hkjn.2014.07.001","volume":"16","author":"Z Ekinci","year":"2014","unstructured":"Ekinci Z, Kenan Bek K, Aytac MB, Karadenizli A, Hancer VS (2014) Renal outcome with eculizumab in two diarrhea-associated hemolytic ureamic syndrome cases with severe neurologic involvement. Hong Kong J Nephrol 16:46\u201349","journal-title":"Hong Kong J Nephrol"},{"key":"6102_CR14","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1177\/0009922814534520","volume":"54","author":"A Saini","year":"2015","unstructured":"Saini A, Emke A, Silva MC, Perlman SJ (2015) Response to eculizumab in Escherichia coli O157:H7 induced hemolytic uremic syndrome with severe neurological manifestations. Clin Pediatr (Phila) 54:387\u2013389","journal-title":"Clin Pediatr (Phila)"},{"key":"6102_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001000","volume":"94","author":"L Pape","year":"2015","unstructured":"Pape L, Hartmann H, Bange FC, Suerbaum S, Bueltmann E, Ahlenstiel-Grunow T (2015) Eculizumab in typical hemolytic uremic syndrome (HUS) With neurological involvement. Medicine (Baltimore) 94:e1000","journal-title":"Medicine (Baltimore)"},{"key":"6102_CR16","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00467-018-3903-9","volume":"33","author":"L Percheron","year":"2018","unstructured":"Percheron L, Gramada R, Tellier S et al (2018) Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study. Pediatr Nephrol 33:1385\u20131394","journal-title":"Pediatr Nephrol"},{"key":"6102_CR17","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/ndt\/gfz158","volume":"35","author":"C Monet-Didailler","year":"2020","unstructured":"Monet-Didailler C, Chevallier A, Godron-Dubrasquet A et al (2020) Outcome of children with Shiga toxin-associated haemolytic uraemic syndrome treated with eculizumab: a matched cohort study. Nephrol Dial Transplant 35:2147\u20132153","journal-title":"Nephrol Dial Transplant"},{"key":"6102_CR18","first-page":"90","volume":"27","author":"B Weber","year":"2022","unstructured":"Weber B, Chan D, Hammer S (2022) Eculizumab use in a temporarily dialysis-dependent patient with Shiga toxin\u2013producing Escherichia coli hemolytic uremic syndrome with neurological complications. J Pediatr Pharmacol Ther 27:90\u201395","journal-title":"J Pediatr Pharmacol Ther"},{"key":"6102_CR19","volume-title":"VTEC infection in Ireland, 2017","author":"HSE Health Protection Surveillance Centre","year":"2019","unstructured":"HSE Health Protection Surveillance Centre (2019) VTEC infection in Ireland, 2017. HSE HPSC, Dublin"},{"key":"6102_CR20","doi-asserted-by":"publisher","unstructured":"Garnier A, Brochard K, Kwon T et al (2023) Efficacy and safety of eculizumab in pediatric patients affected by Shiga toxin-related hemolytic and uremic syndrome: a randomized, placebo-controlled trial. J Am Soc Nephrol. https:\/\/doi.org\/10.1681\/ASN.0000000000000182","DOI":"10.1681\/ASN.0000000000000182"},{"key":"6102_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/00003246-200004000-00043","volume":"28","author":"DH Fiser","year":"2000","unstructured":"Fiser DH, Tilford JM, Roberson PK (2000) Relationship of illness severity and length of stay to functional outcomes in the pediatric intensive care unit: a multi-institutional study. Crit Care Med 28:1173\u20131179","journal-title":"Crit Care Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06102-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-023-06102-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-023-06102-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,30]],"date-time":"2023-11-30T15:03:45Z","timestamp":1701356625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-023-06102-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["6102"],"URL":"https:\/\/doi.org\/10.1007\/s00467-023-06102-w","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Prof. Awan previously served on the medical advisory board of Alexion. All authors have no conflicts, of a financial nature or otherwise, to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}